|
|
Adding Tipifarnib After Imatinib Failure in CML Restores Antitumor Efficacy
|
| Link ID |
1830 |
| Title |
Adding Tipifarnib After Imatinib Failure in CML Restores Antitumor Efficacy |
| Url |
http://www.medscape.com/viewarticle/567870?src=rss |
| Description |
When imatinib therapy has failed in patients with chronic myelogenous leukemia (CML) in chronic phase, adding the farnesyl transferase inhibitor tipifarnib restores activity against the disease and the combination is relatively well-tolerated, researchers report in the November 1st issue of Cancer. Reuters Health Information |
| Category |
Articles > Pharmacists |
| Keywords |
|
| Date |
Dec 22, 2007 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Pharmacists |
| 1. |
Infliximab for Rheumatoid Arthritis Seen Safe in Japanese Patients
|
|
|
Results of a post-marketing surveillance study in Japan provide a "real world" picture of the incidence of adverse reactions associated with infliximab therapy for rheumatoid arthritis (RA), according to a Japanese research team. They conclude that the safety profile is acceptable. Reuters Health Information
|
| 4. |
Incidence of Infections Associated With Leflunomide for RA "Acceptable"
|
|
|
Among patients with rheumatoid arthritis (RA) in New Zealand, the rate of serious infection associated with leflunomide treatment is "acceptable in the context of optimally treating active RA," report Dr. Peter T. Chapman of Christchurch Hospital and colleagues in the November issue of the Journal of Rheumatology. Reuters Health Information
|
|
|
